title: Progastrin a new pro-angiogenic factor in colorectal cancer.
abstract: Angiogenesis is essential in tumor progression and metastatic process, and increased angiogenesis has been associated with poor prognosis and relapse of colorectal cancer (CRC). VEGF has become the main target of anti-angiogenic therapy. However, most patients relapse after an initial response or present a resistance to the treatment. Identification of new pro-angiogenic factors may help to improve anti-angiogenic therapy. In this study, we demonstrated that the pro-hormone progastrin (PG), over-expressed in CRC, recognized as a growth factor, is a potent pro-angiogenic factor. In transgenic mice and human colorectal HPs producing high levels of PG, we correlated PG overexpression with an increased vascularization. In vitro, exogenous PG and conditioned media (CM) from CRC cells producing PG increased endothelial cell proliferation and migration. We also showed that treatment with exogenous PG can increase the ability of endothelial cells to form capillary-like structures. Moreover, we demonstrated that PG enhanced endothelial permeability. The finding that PG stimulated the phosphorylation of vascular endothelial (VE)-cadherin, p125-FAK, paxillin and induced actin remodelling was consistent with a role of these components in PG-stimulated endothelial cell migration and permeability. The pro-angiogenic effects observed with CM were significantly inhibited when CRC cells expressed a PG shRNA. In vivo, we found an important decrease in tumor growth and neovascularization when the CRC cells expressing the PG shRNA were xenografted in mice or in the chick chorioallantoic membrane model. We also observed an increase in the coverage of blood vessels by pericytes and a decrease in endothelial permeability when PG expression was blocked. Our results demonstrate that PG is a new pro-angiogenic factor in CRC and an attractive therapeutic target.
authors.affiliation: INSERM UMR1037-Cancer Research Center of Toulouse (CRCT), University Paul Sabatier Toulouse III, Toulouse, France.
authors.forename: S
authors.initials: S
authors.lastname: Najib
authors.affiliation: INSERM UMR1037-Cancer Research Center of Toulouse (CRCT), University Paul Sabatier Toulouse III, Toulouse, France.
authors.forename: A
authors.initials: A
authors.lastname: Kowalski-Chauvel
authors.affiliation: INSERM UMR1037-Cancer Research Center of Toulouse (CRCT), University Paul Sabatier Toulouse III, Toulouse, France.
authors.forename: C
authors.initials: C
authors.lastname: Do
authors.affiliation: CNRS UMR5237, University of Montpellier I and II, CRBM, Montpellier, France.
authors.forename: S
authors.initials: S
authors.lastname: Roche
authors.affiliation: 1] INSERM UMR1037-Cancer Research Center of Toulouse (CRCT), University Paul Sabatier Toulouse III, Toulouse, France [2] Institut Claudius Regaud, Toulouse, France.
authors.forename: E
authors.initials: E
authors.lastname: Cohen-Jonathan-Moyal
authors.affiliation: INSERM UMR1037-Cancer Research Center of Toulouse (CRCT), University Paul Sabatier Toulouse III, Toulouse, France.
authors.forename: C
authors.initials: C
authors.lastname: Seva
mesh_terms: D000818:Animals; D002478:Cells, Cultured; D002642:Chick Embryo; D015179:Colorectal Neoplasms / Q000098:blood supply* / Q000473:pathology; D005755:Gastrins / Q000235:genetics / Q000494:pharmacology / Q000502:physiology*; D045325:HCT116 Cells; D061307:Human Umbilical Vein Endothelial Cells; D006801:Humans; D051379:Mice; D016513:Mice, SCID; D008822:Mice, Transgenic; D009389:Neovascularization, Pathologic / Q000235:genetics*; D011498:Protein Precursors / Q000235:genetics / Q000494:pharmacology / Q000502:physiology*; D034741:RNA, Small Interfering / Q000494:pharmacology
chemical_list: D005755:Gastrins; D011498:Protein Precursors; D034741:RNA, Small Interfering; C013706:big gastrin
references.citation: Gastroenterology. 1995 Oct;109(4):1142-53
references.pmid: 7557079
references.citation: Nat Protoc. 2006;1(1):85-91
references.pmid: 17406216
references.citation: Cancer Res. 1995 Sep 15;55(18):3964-8
references.pmid: 7664263
references.citation: Proc Natl Acad Sci U S A. 1999 Aug 17;96(17):9815-20
references.pmid: 10449777
references.citation: J Gastrointest Oncol. 2013 Sep;4(3):253-63
references.pmid: 23997938
references.citation: Am J Physiol Gastrointest Liver Physiol. 2003 Dec;285(6):G1097-110
references.pmid: 12881229
references.citation: J Biol Chem. 2012 Nov 30;287(49):41458-68
references.pmid: 23055519
references.citation: Nat Cell Biol. 2006 Nov;8(11):1223-34
references.pmid: 17060906
references.citation: Cancer Res. 2006 Apr 1;66(7):3504-12
references.pmid: 16585174
references.citation: J Physiol. 2014 Jul 15;592(14):2951-8
references.pmid: 24665102
references.citation: J Biol Chem. 1997 Jun 13;272(24):15442-51
references.pmid: 9182576
references.citation: Nat Rev Cancer. 2008 Aug;8(8):592-603
references.pmid: 18650835
references.citation: Endocrinology. 2003 Jan;144(1):201-11
references.pmid: 12488346
references.citation: Int J Cancer. 2010 Jun 15;126(12):2847-57
references.pmid: 19876923
references.citation: Nat Med. 2003 Jun;9(6):669-76
references.pmid: 12778165
references.citation: Cancer Res. 2005 Apr 1;65(7):2770-7
references.pmid: 15805277
references.citation: J Cell Sci. 2003 Apr 1;116(Pt 7):1187-97
references.pmid: 12615962
references.citation: J Biol Chem. 2009 Sep 18;284(38):25602-11
references.pmid: 19633358
references.citation: Gastroenterology. 2000 Jul;119(1):162-71
references.pmid: 10889165
references.citation: J Biol Chem. 2001 Mar 16;276(11):7791-6
references.pmid: 11113148
references.citation: Dev Cell. 2012 Jan 17;22(1):146-57
references.pmid: 22264731
references.citation: Br J Cancer. 1998 Mar;77(6):998-1002
references.pmid: 9528847
references.citation: Oncogene. 2008 Sep 18;27(42):5599-611
references.pmid: 18521082
references.citation: Am J Physiol Gastrointest Liver Physiol. 2003 Feb;284(2):G328-39
references.pmid: 12388191
references.citation: Oncogene. 2010 Mar 4;29(9):1303-15
references.pmid: 20010872
references.citation: Cell. 1999 Jul 23;98(2):147-57
references.pmid: 10428027
references.citation: Gut. 2000 Dec;47(6):820-4
references.pmid: 11076881
references.citation: J Clin Invest. 1996 Oct 15;98(8):1918-29
references.pmid: 8878444
references.citation: Gastroenterology. 1993 Apr;104(4):1099-107
references.pmid: 8462798
references.citation: J Cell Sci. 1998 Jul;111 ( Pt 13):1853-65
references.pmid: 9625748
references.citation: Gastroenterology. 2013 Oct;145(4):820-30.e10
references.pmid: 23891976
references.citation: Gut. 1993 Jan;34(1):90-5
references.pmid: 8432459
references.citation: Nat Rev Mol Cell Biol. 2004 Apr;5(4):261-70
references.pmid: 15071551
references.citation: Cancer Prev Res (Phila). 2012 Apr;5(4):675-84
references.pmid: 22366915
references.citation: Colorectal Dis. 2007 Jan;9(1):3-14
references.pmid: 17181841
references.citation: Cancer Lett. 2012 Jul 28;320(2):130-7
references.pmid: 22425960
references.citation: Gastroenterology. 2013 Jul;145(1):197-208, e3
references.pmid: 23523669
references.citation: Gastroenterology. 1997 Nov;113(5):1576-88
references.pmid: 9352860
references.citation: Br J Cancer. 2006 Jun 19;94(12):1823-32
references.pmid: 16773076
references.citation: Gut. 2001 Jan;48(1):47-52
references.pmid: 11115822